Journal article
Review article: 5-Aminosalicylate formulations for the treatment of ulcerative colitis - Methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa
GR Lichtenstein, MA Kamm
Alimentary Pharmacology and Therapeutics | Published : 2008
Abstract
Background: Many oral 5-aminosalicylic acid (5-ASA) formulations are designed to maximize 5-ASA release in the colon where it acts topically on the colonic mucosa. Delayed-release formulations and azo-prodrugs minimize 5-ASA absorption in the upper gastrointestinal (GI) tract. Aims: To review methods for assessing 5-ASA release and colonic distribution from oral formulations, and the potential use of this information for guiding clinical decisions. Methods: PubMed and recent conference abstracts were searched for articles describing techniques used to assess 5-ASA release from ulcerative colitis (UC) therapies. Results: In-vitro GI models, although unable to simulate more complex aspects of ..
View full abstractGrants
Funding Acknowledgements
Declaration of personal interests: Gary Lichtenstein has served as a speaker, a consultant and an advisory board for member for Shire Pharmaceuticals Inc., and has received research funding from Shire Pharmaceuticals Inc. Michael Kamm has served as a speaker, a consultant and an advisory board member for Shire Pharmaceuticals Inc., and has received research funding from Shire Pharmaceuticals Inc. Declaration of funding interests: This research was funded by Shire Pharmaceuticals Inc. The preparation of this paper was funded in part by Shire Pharmaceuticals Inc. Writing support was provided by Duncan Campbell of GeoMed and Noel Curtis (contract writer) and funded by Shire Pharmaceuticals Inc.